Beijing Xin Hang Rui Kang Bio-Technology Co., Ltd.

Xin Hang Rui Kang Bio-Technology is a China-based biopharmaceutical company specializing in the development of next-generation AAV-mediated gene therapies for rare and chronic diseases. The company leverages proprietary technology to optimize viral capsids and tissue-specific promoters, aiming to enhance the safety, precision, and durability of genetic medicines. Its current pipeline primarily focuses on lysosomal storage disorders, including Fabry disease and Pompe disease, as well as hematological conditions like Hemophilia B. Founded by veterans in the gene therapy field, the company operates out of Beijing and has secured significant venture capital to advance its IND-enabling studies.